NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs071180092

Registered date:29/03/2019

Treatment of ocular toxoplasmosis with pyrimethamine/sulfadiazine

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedOcular toxoplasmosis
Date of first enrollment14/04/2020
Target sample size35
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Treatment with un-licensed medicine

Outcome(s)

Primary OutcomeImprovement of visual acuity 24 weeks after treatment
Secondary Outcome1) reduction ratio of affected retina area 2) duration until scar formation 3) incidence of abdominal symptoms 4) incidence of pancytopenia 5) incidence of acute renal failure 6) incidence of hepatic dysfunction 7) incidence of skin eruption (e.g. erythema)

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderBoth
Include criteriaPatients with active uveitis and one of the following findings #1 Toxoplasma DNA positive #2 high anti-Toxoplasma IgG concentration in vitreous humor #3 serum anti-Toxoplasma IgG positive
Exclude criteria#1 HIV positive patients #2 patients allergic to test compounds #3 patients with megaloblastic anemia due to folate deficiency #4 No consent is given from the patient him/herself nor a legally authorized representative/guardian of the patient #5 patients principal investigator judged inappropriate

Related Information

Contact

Public contact
Name Haruhiko Maruyama
Address 5200 Kihara, Kiyotake, Miyazaki 889-1692, JAPAN Miyazaki Japan 889-1692
Telephone +81-985-85-0990
E-mail hikomaru@med.miyazaki-u.ac.jp
Affiliation University of Miyazaki
Scientific contact
Name Haruhiko Maruyama
Address 5200 Kihara, Kiyotake, Miyazaki 889-1692, JAPAN Miyazaki Japan 889-1692
Telephone +81-985-85-0990
E-mail hikomaru@med.miyazaki-u.ac.jp
Affiliation University of Miyazaki Hospital